The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. In a phase III trial in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzogani, Kyriaki, Camarero Jiménez, Jorge, Garcia, Isabel, Sancho‐López, Arantxa, Martin, Marc, Moreau, Alexandre, Demolis, Pierre, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: EMA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679835/
https://www.ncbi.nlm.nih.gov/pubmed/28935772
http://dx.doi.org/10.1634/theoncologist.2017-0184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679835/
https://www.ncbi.nlm.nih.gov/pubmed/28935772
http://dx.doi.org/10.1634/theoncologist.2017-0184

Ejemplares similares